Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 41 to 50 of 797

TitleReference numberPublishedLast updated
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283

Results per page

  1. 10
  2. 25
  3. 50
  4. All